Response to Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML"

Sci Signal. 2016 Aug 9;9(440):tc2. doi: 10.1126/scisignal.aad9777.

Abstract

Arsenic trioxide chemotherapy cures acute promyelocytic leukemia by inducing the ubiquitylation of an oncogenic fusion protein containing promyelocytic leukemia protein (PML) subsequent to modification of PML by SUMO1 and SUMO2. We proposed that the SUMO switch at Lys(65) of PML enhanced subsequent SUMO2 conjugation to Lys(160) and consequent RNF4-dependent ubiquitylation of PML. Ferhi et al note differences between their experimental system and ours regarding the outcome and mechanisms of SUMO-dependent PML signaling. When confronted by apparently contradictory data, it is appropriate to drill down to where the differences could lie.

Publication types

  • Comment

MeSH terms

  • Arsenic*
  • Nuclear Proteins / genetics
  • Promyelocytic Leukemia Protein
  • Tumor Suppressor Proteins / genetics
  • Ubiquitination

Substances

  • Nuclear Proteins
  • Promyelocytic Leukemia Protein
  • Tumor Suppressor Proteins
  • Arsenic